{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:48:56Z","timestamp":1790952536838,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T00:00:00Z","timestamp":1513641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100001061","name":"Rebecca L. Cooper Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["ECF APP1111136"],"award-info":[{"award-number":["ECF APP1111136"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009844","name":"PA Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009844","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>\n                    Clozapine causes obesity and type 2 diabetes (T2DM). Glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonists (e.g. exenatide) can counter clozapine\u2010associated GLP\u20101 dysregulation in animals, and may be beneficial in people on clozapine. This randomized, controlled, open\u2010label, pilot trial evaluated weekly exenatide for weight loss among clozapine\u2010treated obese adults with schizophrenia, with or without T2DM. A total of 28 outpatients were randomized to once\u2010weekly extended\u2010release subcutaneous exenatide or usual care for 24\u2009weeks. The primary outcome was proportion of participants with &gt;5% weight loss. All 28 participants completed the study; 3\/14 in the exenatide group and 2\/14 in the usual care group had T2DM. Six people on exenatide achieved &gt;5% weight loss vs one receiving usual care (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009.029). Compared with usual care, participants on exenatide had greater mean weight loss (\u22125.29 vs \u22121.12\u2009kg;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009.015) and body mass index reduction (\u22121.78 vs \u22120.39\u2009kg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009.019), and reduced fasting glucose (\u22120.34 vs 0.39\u2009mmol\/L;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009.036) and glycated haemoglobin levels (\u22120.21% vs 0.03%;\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u2009.004). There were no significant differences in other metabolic syndrome components. Exenatide may be a promising therapeutic agent for glycaemic control and weight loss in clozapine\u2010treated people with obesity, and could assist in reducing clozapine\u2010associated cardio\u2010metabolic morbidity and mortality.\n                  <\/jats:p>","DOI":"10.1111\/dom.13167","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T08:02:43Z","timestamp":1512028963000},"page":"1050-1055","source":"Crossref","is-referenced-by-count":93,"title":["Treatment of clozapine\u2010associated obesity and diabetes with exenatide in adults with schizophrenia:\n                    <scp>A<\/scp>\n                    randomized controlled trial (\n                    <scp>CODEX<\/scp>\n                    )"],"prefix":"10.1111","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan J","family":"Siskind","sequence":"first","affiliation":[{"name":"Metro South Addiction and Mental Health Service  Brisbane Australia"},{"name":"School of Medicine University of Queensland  Brisbane Australia"},{"name":"Queensland Centre for Mental Health Research  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony W.","family":"Russell","sequence":"additional","affiliation":[{"name":"School of Medicine University of Queensland  Brisbane Australia"},{"name":"Department of Endocrinology Princess Alexandra Hospital  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Gamble","sequence":"additional","affiliation":[{"name":"Queensland Centre for Mental Health Research  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Winckel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology Princess Alexandra Hospital  Brisbane Australia"},{"name":"School of Pharmacy University of Queensland  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Mayfield","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Logan Hospital  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Hollingworth","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Queensland  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hickman","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Dietetics Princess Alexandra Hospital  Brisbane Australia"},{"name":"Mater Research Institute  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Siskind","sequence":"additional","affiliation":[{"name":"Centre for Accident Research and Road Safety \u2010 Queensland Queensland University of Technology  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kisely","sequence":"additional","affiliation":[{"name":"Metro South Addiction and Mental Health Service  Brisbane Australia"},{"name":"School of Medicine University of Queensland  Brisbane Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,12,19]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12700"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.115.177261"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0905"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200105033441801"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1807-1"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156208"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-15-0074"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2009.07.011"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115625496"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12119"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.115.001073"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjpo.bp.116.003103"},{"key":"e_1_2_6_14_1","volume-title":"Bydureon (Exenatide) Australian Approved Product Information","author":"AstraZeneca","year":"2015"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8223(97)00126-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12795"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.13167","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.13167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:41:15Z","timestamp":1761867675000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.13167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,19]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/dom.13167"],"URL":"https:\/\/doi.org\/10.1111\/dom.13167","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,19]]}}}